Published in Cancer Res on January 01, 2008
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet (2010) 1.82
Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics (2009) 1.62
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev (2011) 1.56
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol (2009) 1.23
Beyond DNA repair: DNA-PK function in cancer. Cancer Discov (2014) 1.16
Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer (2010) 1.16
Fusion in the ETS gene family and prostate cancer. Br J Cancer (2008) 1.12
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 1.11
Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab (2011) 1.07
Translocations in epithelial cancers. Biochim Biophys Acta (2009) 1.04
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
Urinary biomarkers for prostate cancer: a review. Asian J Androl (2013) 1.02
Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res (2014) 1.01
A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Mol Cancer (2009) 1.01
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol (2011) 1.00
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res (2011) 0.99
Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis (2012) 0.98
Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res (2012) 0.98
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol (2013) 0.97
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res (2013) 0.96
The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem (2013) 0.95
Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol (2014) 0.93
Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. Biomed Res Int (2013) 0.93
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One (2012) 0.91
Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines. Carcinogenesis (2009) 0.91
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Mol Cancer (2014) 0.90
Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation. PLoS One (2011) 0.89
ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One (2014) 0.89
5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PLoS One (2013) 0.88
The genomic landscape of prostate cancer. Int J Mol Sci (2013) 0.88
Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr Drug Targets (2013) 0.88
Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS One (2013) 0.88
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol (2013) 0.86
RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites. Small GTPases (2012) 0.85
Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med (2015) 0.84
Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res (2014) 0.83
Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells. Genes Cancer (2011) 0.82
Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer. Neoplasia (2013) 0.82
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
C-kit signaling promotes proliferation and invasion of colorectal mucinous adenocarcinoma in a murine model. Oncotarget (2015) 0.81
Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl (2016) 0.81
Microarray analysis of port wine stains before and after pulsed dye laser treatment. Lasers Surg Med (2013) 0.81
Genomic rearrangements in prostate cancer. Curr Opin Urol (2015) 0.80
Hypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random Primers. J Cancer (2015) 0.80
The biology of castration-resistant prostate cancer. Curr Probl Cancer (2014) 0.80
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget (2015) 0.80
ETS gene fusions and prostate cancer. Am J Transl Res (2009) 0.80
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell (2017) 0.78
The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol (2011) 0.78
Integrative biology--a strategy for systems biomedicine. Nat Rev Genet (2009) 0.78
Variant splicing and influence of ionizing radiation on human endogenous retrovirus K (HERV-K) transcripts in cancer cell lines. PLoS One (2013) 0.78
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology (2012) 0.78
Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5. Nucleic Acids Res (2017) 0.77
Prognostic gene signature identification using causal structure learning: applications in kidney cancer. Cancer Inform (2015) 0.77
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol Ther (2014) 0.77
ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer. ISRN Urol (2013) 0.77
Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Transl Oncol (2013) 0.77
The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Res (2014) 0.77
Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients. J Transl Med (2016) 0.77
ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol (2015) 0.76
Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Med (2013) 0.76
Molecular subtyping of prostate cancer. Curr Opin Urol (2016) 0.76
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Significantly higher expression levels of androgen receptor are associated with erythroblastosis virus E26 oncogene related gene positive prostate cancer. Am J Clin Exp Urol (2014) 0.75
Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion. Oncotarget (2016) 0.75
ETV4 and AP1 transcription factors form multivalent interactions with three sites on the MED25 activator-interacting domain. J Mol Biol (2017) 0.75
LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs. Elife (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81